The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery

James S. Brock, Marc S Sussman, Marguerite Wamsley, Ronnie Mintzer, F. Gregory Baumann, Thomas S. Riles

Research output: Contribution to journalArticle

Abstract

To examine the influence of human immunodeficiency virus (HIV) infection on complications in dialysis access surgery, a review was performed on patients undergoing hemodialysis at two major metropolitan medical centers over a 30-month period. One hundred eight patients underwent a total of 169 graft procedures; mean follow-up was 14 1 2 months. There were 18 (17%) patients who were HIV-positive who had no symptoms, 11 (10%) patients with acquired immunodeficiency syndrome (AIDS), and 79 (73%) patients who were HIV-negative. Twenty-three percent ( 25 108) of patients had a history of intravenous drug abuse (IVDA), most of whom also had either AIDS or asymptomatic HIV infection. Dialysis procedures included 44 autogenous reconstructions (26%), 117 polytetrafluoroethylene (PTFE) grafts (69%), and 8 (5%) procedures of unknown type. Arteriovenous fistula or graft thrombosis was a frequent complication. The overall 12-month graft patency rate was 41%, and patients with HIV infection or a history of IVDA did not have a significantly increased risk of thrombosis. Multivariate analysis showed that the use of PTFE as opposed to autogenous reconstruction was the only significant risk factor found for occlusion within the first 12 months after operation (p <0.01). Twenty-five graft infections occurred, all in PTFE grafts. The PTFE graft infection rate was 43% in patients with AIDS, 36% in patients who were HIV-positive and who had no symptoms, and 15% in patients who were HIV-negative (p <0.05). Patients with a history of IVDA had a 41% PTFE graft infection rate versus a 13% infection rate in patients who did not have a history of IVDA (p <0.01). Patients with AIDS had a markedly limited cumulative survival rate, 62% at 1 year after operation. In conjunction with these data, guidelines are discussed for the management of hemodialysis access in patients with HIV infection. In particular, in such patients PTFE arteriovenous grafts should be avoided because of alarmingly high graft infection rates.

Original languageEnglish (US)
Pages (from-to)904-912
Number of pages9
JournalJournal of Vascular Surgery
Volume16
Issue number6
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Intravenous Substance Abuse
Virus Diseases
Renal Dialysis
HIV
Transplants
Polytetrafluoroethylene
Acquired Immunodeficiency Syndrome
Infection
Dialysis
Thrombosis
Arteriovenous Fistula

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. / Brock, James S.; Sussman, Marc S; Wamsley, Marguerite; Mintzer, Ronnie; Baumann, F. Gregory; Riles, Thomas S.

In: Journal of Vascular Surgery, Vol. 16, No. 6, 1992, p. 904-912.

Research output: Contribution to journalArticle

Brock, James S. ; Sussman, Marc S ; Wamsley, Marguerite ; Mintzer, Ronnie ; Baumann, F. Gregory ; Riles, Thomas S. / The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. In: Journal of Vascular Surgery. 1992 ; Vol. 16, No. 6. pp. 904-912.
@article{f3dbda861024474ca952dab50b3f2a91,
title = "The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery",
abstract = "To examine the influence of human immunodeficiency virus (HIV) infection on complications in dialysis access surgery, a review was performed on patients undergoing hemodialysis at two major metropolitan medical centers over a 30-month period. One hundred eight patients underwent a total of 169 graft procedures; mean follow-up was 14 1 2 months. There were 18 (17{\%}) patients who were HIV-positive who had no symptoms, 11 (10{\%}) patients with acquired immunodeficiency syndrome (AIDS), and 79 (73{\%}) patients who were HIV-negative. Twenty-three percent ( 25 108) of patients had a history of intravenous drug abuse (IVDA), most of whom also had either AIDS or asymptomatic HIV infection. Dialysis procedures included 44 autogenous reconstructions (26{\%}), 117 polytetrafluoroethylene (PTFE) grafts (69{\%}), and 8 (5{\%}) procedures of unknown type. Arteriovenous fistula or graft thrombosis was a frequent complication. The overall 12-month graft patency rate was 41{\%}, and patients with HIV infection or a history of IVDA did not have a significantly increased risk of thrombosis. Multivariate analysis showed that the use of PTFE as opposed to autogenous reconstruction was the only significant risk factor found for occlusion within the first 12 months after operation (p <0.01). Twenty-five graft infections occurred, all in PTFE grafts. The PTFE graft infection rate was 43{\%} in patients with AIDS, 36{\%} in patients who were HIV-positive and who had no symptoms, and 15{\%} in patients who were HIV-negative (p <0.05). Patients with a history of IVDA had a 41{\%} PTFE graft infection rate versus a 13{\%} infection rate in patients who did not have a history of IVDA (p <0.01). Patients with AIDS had a markedly limited cumulative survival rate, 62{\%} at 1 year after operation. In conjunction with these data, guidelines are discussed for the management of hemodialysis access in patients with HIV infection. In particular, in such patients PTFE arteriovenous grafts should be avoided because of alarmingly high graft infection rates.",
author = "Brock, {James S.} and Sussman, {Marc S} and Marguerite Wamsley and Ronnie Mintzer and Baumann, {F. Gregory} and Riles, {Thomas S.}",
year = "1992",
doi = "10.1016/0741-5214(92)90053-B",
language = "English (US)",
volume = "16",
pages = "904--912",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery

AU - Brock, James S.

AU - Sussman, Marc S

AU - Wamsley, Marguerite

AU - Mintzer, Ronnie

AU - Baumann, F. Gregory

AU - Riles, Thomas S.

PY - 1992

Y1 - 1992

N2 - To examine the influence of human immunodeficiency virus (HIV) infection on complications in dialysis access surgery, a review was performed on patients undergoing hemodialysis at two major metropolitan medical centers over a 30-month period. One hundred eight patients underwent a total of 169 graft procedures; mean follow-up was 14 1 2 months. There were 18 (17%) patients who were HIV-positive who had no symptoms, 11 (10%) patients with acquired immunodeficiency syndrome (AIDS), and 79 (73%) patients who were HIV-negative. Twenty-three percent ( 25 108) of patients had a history of intravenous drug abuse (IVDA), most of whom also had either AIDS or asymptomatic HIV infection. Dialysis procedures included 44 autogenous reconstructions (26%), 117 polytetrafluoroethylene (PTFE) grafts (69%), and 8 (5%) procedures of unknown type. Arteriovenous fistula or graft thrombosis was a frequent complication. The overall 12-month graft patency rate was 41%, and patients with HIV infection or a history of IVDA did not have a significantly increased risk of thrombosis. Multivariate analysis showed that the use of PTFE as opposed to autogenous reconstruction was the only significant risk factor found for occlusion within the first 12 months after operation (p <0.01). Twenty-five graft infections occurred, all in PTFE grafts. The PTFE graft infection rate was 43% in patients with AIDS, 36% in patients who were HIV-positive and who had no symptoms, and 15% in patients who were HIV-negative (p <0.05). Patients with a history of IVDA had a 41% PTFE graft infection rate versus a 13% infection rate in patients who did not have a history of IVDA (p <0.01). Patients with AIDS had a markedly limited cumulative survival rate, 62% at 1 year after operation. In conjunction with these data, guidelines are discussed for the management of hemodialysis access in patients with HIV infection. In particular, in such patients PTFE arteriovenous grafts should be avoided because of alarmingly high graft infection rates.

AB - To examine the influence of human immunodeficiency virus (HIV) infection on complications in dialysis access surgery, a review was performed on patients undergoing hemodialysis at two major metropolitan medical centers over a 30-month period. One hundred eight patients underwent a total of 169 graft procedures; mean follow-up was 14 1 2 months. There were 18 (17%) patients who were HIV-positive who had no symptoms, 11 (10%) patients with acquired immunodeficiency syndrome (AIDS), and 79 (73%) patients who were HIV-negative. Twenty-three percent ( 25 108) of patients had a history of intravenous drug abuse (IVDA), most of whom also had either AIDS or asymptomatic HIV infection. Dialysis procedures included 44 autogenous reconstructions (26%), 117 polytetrafluoroethylene (PTFE) grafts (69%), and 8 (5%) procedures of unknown type. Arteriovenous fistula or graft thrombosis was a frequent complication. The overall 12-month graft patency rate was 41%, and patients with HIV infection or a history of IVDA did not have a significantly increased risk of thrombosis. Multivariate analysis showed that the use of PTFE as opposed to autogenous reconstruction was the only significant risk factor found for occlusion within the first 12 months after operation (p <0.01). Twenty-five graft infections occurred, all in PTFE grafts. The PTFE graft infection rate was 43% in patients with AIDS, 36% in patients who were HIV-positive and who had no symptoms, and 15% in patients who were HIV-negative (p <0.05). Patients with a history of IVDA had a 41% PTFE graft infection rate versus a 13% infection rate in patients who did not have a history of IVDA (p <0.01). Patients with AIDS had a markedly limited cumulative survival rate, 62% at 1 year after operation. In conjunction with these data, guidelines are discussed for the management of hemodialysis access in patients with HIV infection. In particular, in such patients PTFE arteriovenous grafts should be avoided because of alarmingly high graft infection rates.

UR - http://www.scopus.com/inward/record.url?scp=0026622032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026622032&partnerID=8YFLogxK

U2 - 10.1016/0741-5214(92)90053-B

DO - 10.1016/0741-5214(92)90053-B

M3 - Article

C2 - 1460717

AN - SCOPUS:0026622032

VL - 16

SP - 904

EP - 912

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 6

ER -